DE3435517A1 - Vesikel bildende massen - Google Patents
Vesikel bildende massenInfo
- Publication number
- DE3435517A1 DE3435517A1 DE19843435517 DE3435517A DE3435517A1 DE 3435517 A1 DE3435517 A1 DE 3435517A1 DE 19843435517 DE19843435517 DE 19843435517 DE 3435517 A DE3435517 A DE 3435517A DE 3435517 A1 DE3435517 A1 DE 3435517A1
- Authority
- DE
- Germany
- Prior art keywords
- hydrocarbon group
- carbon atoms
- vesicle
- group
- vesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 alkanolammonium Chemical class 0.000 claims description 25
- 239000004094 surface-active agent Substances 0.000 claims description 25
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000005622 tetraalkylammonium hydroxides Chemical class 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000006364 carbonyl oxy methylene group Chemical group [H]C([H])([*:2])OC([*:1])=O 0.000 claims 1
- 235000019256 formaldehyde Nutrition 0.000 claims 1
- 239000000446 fuel Substances 0.000 claims 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical group C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 claims 1
- GJSGYPDDPQRWPK-UHFFFAOYSA-N tetrapentylammonium Chemical compound CCCCC[N+](CCCCC)(CCCCC)CCCCC GJSGYPDDPQRWPK-UHFFFAOYSA-N 0.000 claims 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 17
- 239000002502 liposome Substances 0.000 description 16
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 11
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- FRXGWNKDEMTFPL-UHFFFAOYSA-N dioctadecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCCCC FRXGWNKDEMTFPL-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- GBMTXDSKXXXLHM-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;dioctadecyl hydrogen phosphate Chemical compound NCCCC[C@H](N)C(O)=O.CCCCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCCCC GBMTXDSKXXXLHM-ZSCHJXSPSA-N 0.000 description 2
- SJZZDLZBGLQGCG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dioctadecyl hydrogen phosphate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCCCC SJZZDLZBGLQGCG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZJUUTZOYDQREOQ-UHFFFAOYSA-N C(O)CN.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O Chemical compound C(O)CN.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O ZJUUTZOYDQREOQ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- MFDGGSJHJZUCHT-UHFFFAOYSA-N 1,4-dioctadecoxy-1,4-dioxobutane-2-sulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCCCCCCCCCCCC MFDGGSJHJZUCHT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- UJUWNSRXIGHHKM-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;didodecyl hydrogen phosphate Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCOP([O-])(=O)OCCCCCCCCCCCC UJUWNSRXIGHHKM-UHFFFAOYSA-N 0.000 description 1
- BIHQJMSIEXRWPS-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dodecyl dihydrogen phosphate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOP(O)(O)=O BIHQJMSIEXRWPS-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- SRSLTXZRJNCQFO-UHFFFAOYSA-N N(CCO)CCO.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O Chemical compound N(CCO)CCO.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O SRSLTXZRJNCQFO-UHFFFAOYSA-N 0.000 description 1
- CBLKKZLBPKGXOF-UHFFFAOYSA-N N1CCOCC1.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O Chemical compound N1CCOCC1.P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)O CBLKKZLBPKGXOF-UHFFFAOYSA-N 0.000 description 1
- CZZQNRIVYWGCLU-UHFFFAOYSA-L P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)[O-].[OH-].C(C)[N+](CC)(CC)CC.C(C)[N+](CC)(CC)CC Chemical compound P(=O)(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)[O-].[OH-].C(C)[N+](CC)(CC)CC.C(C)[N+](CC)(CC)CC CZZQNRIVYWGCLU-UHFFFAOYSA-L 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- TXQVDVNAKHFQPP-UHFFFAOYSA-N [3-hydroxy-2,2-bis(hydroxymethyl)propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)CO TXQVDVNAKHFQPP-UHFFFAOYSA-N 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WFFZELZOEWLYNK-CLFAGFIQSA-N bis[(z)-octadec-9-enyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(O)(=O)OCCCCCCCC\C=C/CCCCCCCC WFFZELZOEWLYNK-CLFAGFIQSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NWEKXBVHVALDOL-UHFFFAOYSA-N butylazanium;hydroxide Chemical compound [OH-].CCCC[NH3+] NWEKXBVHVALDOL-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- OTOYAWQBIJQTRP-UHFFFAOYSA-N dihexadecyl phosphate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCOP([O-])(=O)OCCCCCCCCCCCCCCCC OTOYAWQBIJQTRP-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XGZOMURMPLSSKQ-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N(CCO)CCO XGZOMURMPLSSKQ-UHFFFAOYSA-N 0.000 description 1
- UTTVXKGNTWZECK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)[O-] UTTVXKGNTWZECK-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- GVRNEIKWGDQKPS-UHFFFAOYSA-N nonyl benzenesulfonate Chemical compound CCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVRNEIKWGDQKPS-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- UUYIGEHMMJXBBE-UHFFFAOYSA-M potassium;dioctadecyl phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCCCOP([O-])(=O)OCCCCCCCCCCCCCCCCCC UUYIGEHMMJXBBE-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- HCYWSHCYEUEVRZ-UHFFFAOYSA-M sodium N-dodecylcarbamate Chemical compound C(CCCCCCCCCCC)NC(=O)[O-].[Na+] HCYWSHCYEUEVRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- JSMHQMIPUOPQLR-UHFFFAOYSA-M sodium;dioctadecyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOP([O-])(=O)OCCCCCCCCCCCCCCCCCC JSMHQMIPUOPQLR-UHFFFAOYSA-M 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58181628A JPS6072830A (ja) | 1983-09-29 | 1983-09-29 | ベシクル用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3435517A1 true DE3435517A1 (de) | 1985-04-18 |
Family
ID=16104098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19843435517 Withdrawn DE3435517A1 (de) | 1983-09-29 | 1984-09-27 | Vesikel bildende massen |
Country Status (4)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
DE4107152A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparate zur nichtinvasiven verabreichung von antidiabetica |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK86988A (da) * | 1987-02-25 | 1988-08-26 | Takeda Chemical Industries Ltd | Liposompraeparat og anvendelse deraf |
US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
JPH0720857B2 (ja) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
WO1991016040A1 (en) * | 1990-04-18 | 1991-10-31 | Takeda Chemical Industries, Ltd. | Liposome composition |
EP0550463B1 (en) * | 1990-09-06 | 1996-06-26 | S.C. Johnson & Son, Inc. | Stabilized liposome process and compositions containing them |
US5741518A (en) * | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
FR2694884B1 (fr) * | 1992-08-03 | 1996-10-18 | Oreal | Composition formee d'une dispersion aqueuse de vesicules de lipides amphiphiles non-ioniques stabilisees. |
FR2694893A1 (fr) * | 1992-08-03 | 1994-02-25 | Oreal | Composition formée d'une dispersion aqueuse de vésicules de lipides amphiphiles non-ioniques stabilisées. |
US5464696A (en) * | 1992-08-13 | 1995-11-07 | Bracco International B.V. | Particles for NMR imaging |
AU9740498A (en) * | 1998-09-01 | 2000-03-21 | Idea Ag | Electrically controlled transport of charged penetrants across barriers |
US6080211A (en) * | 1999-02-19 | 2000-06-27 | Igen, Inc. | Lipid vesicle-based fuel additives and liquid energy sources containing same |
EP1264632A1 (de) * | 2001-06-08 | 2002-12-11 | Cognis Iberia, S.L. | Verwendung von Alkyl(ether)phosphaten(III) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2193871B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-07-25 | 1977-07-22 | Colgate Palmolive Co | |
SE408714B (sv) * | 1974-11-25 | 1979-07-02 | Berol Kemi Ab | Flytande vattenhaltigt tvett- och rengoringsmedel innehallande en ytaktiv del och komplexbildare |
FR2315991A1 (fr) * | 1975-06-30 | 1977-01-28 | Oreal | Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes |
FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
EP0102324A3 (de) * | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
-
1983
- 1983-09-29 JP JP58181628A patent/JPS6072830A/ja active Granted
-
1984
- 1984-09-07 GB GB08422629A patent/GB2151203B/en not_active Expired
- 1984-09-26 FR FR8414761A patent/FR2552666B1/fr not_active Expired
- 1984-09-27 DE DE19843435517 patent/DE3435517A1/de not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
DE4107152A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparate zur nichtinvasiven verabreichung von antidiabetica |
Also Published As
Publication number | Publication date |
---|---|
JPS6072830A (ja) | 1985-04-24 |
GB2151203A (en) | 1985-07-17 |
FR2552666B1 (fr) | 1988-05-27 |
GB8422629D0 (en) | 1984-10-10 |
JPH0326165B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-04-10 |
GB2151203B (en) | 1987-01-07 |
FR2552666A1 (fr) | 1985-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2629100C3 (de) | Dispersion von Kügelchen und Verfahren zu ihrer Herstellung | |
DE3435516A1 (de) | Massen zur ausbildung von vesikeln | |
DE69717095T2 (de) | Topische vitamin d zusammensetzung auf liposomenbasis | |
DE69521896T2 (de) | Präparat auf lipidbasis, das diacylglyzerin, ein phospholipid, eine polare flüssigkeit und biologisch aktives material enthält | |
DE69511423T2 (de) | Stabile umkehr- und mehrfachfluorkohlenstoffemulsionen | |
DE69216650T2 (de) | Analgetische Zusammensetzungen | |
DE3713493C3 (de) | Kosmetisches oder pharmazeutisches Mittel auf Basis einer wäßrigen Dispersion von Lipidkügelchen | |
DE3435517A1 (de) | Vesikel bildende massen | |
DE69103944T2 (de) | Durchsichtiger Stift. | |
DE3783039T2 (de) | Membran lipid zusammensetzung und verfahren zur herstellung. | |
DE3713494A1 (de) | Verfahren zur herstellung einer dispersion von lipidkuegelchen in einer waessrigen phase und nach diesem verfahren erhaeltliche dispersionen | |
DE69112849T2 (de) | Wässrige phospholipidvesikeldispersion, verfahren zu deren herstellung sowie deren verwendung. | |
DE69711237T2 (de) | Lokalanästhetikum zur aüsserlichen anwendung | |
DD266506A5 (de) | Verfahren zur herstellung einer pharmazeutischen band-zusammensetzung | |
DE19614823A1 (de) | Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge | |
DE2557615A1 (de) | Neue niclosamid-suspensionsformulierungen | |
DE102005063375A1 (de) | Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen | |
DE3852409T2 (de) | Aus Phospholipiden bestehende Darreichungsform für wasserunlösliche Wirksubstanzen. | |
EP0707847A1 (de) | Ketoprofen Liposomen | |
AT379309B (de) | Verfahren zur herstellung einer topischen benzoylperoxidzusammensetzung | |
DE69122810T2 (de) | Liposomen | |
DE69113036T2 (de) | Verzögerte arzneistoffabgabe durch topische anwendung bioadhäsiver liposomen. | |
DE3884945T2 (de) | Emulsion für parenterale verabreichung. | |
DE4110779A1 (de) | Liposomale formulierungen antimykotischer, antibakterieller und/oder antiphlogistischer arzneimittel fuer die lokale und vaginale anwendung | |
WO1997021428A1 (de) | Cortisolspray zur topischen verabreichung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8141 | Disposal/no request for examination |